These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33550714)

  • 1. Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma.
    Grandoni J; Duretz V; Bonzo D; Evans S; Plantier JL
    Haemophilia; 2021 Mar; 27(2):321-328. PubMed ID: 33550714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
    Levy GG; Asikanius E; Kuebler P; Benchikh El Fegoun S; Esbjerg S; Seremetis S
    J Thromb Haemost; 2019 Sep; 17(9):1470-1477. PubMed ID: 31124272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
    Kizilocak H; Marquez-Casas E; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Sep; 27(5):730-735. PubMed ID: 34115433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgery with emicizumab prophylaxis for two paediatric patients with severe haemophilia A with inhibitors.
    Lockhart M; Tardy-Poncet B; Montmartin A; Noyel P; Thouvenin S; Berger C
    Pediatr Blood Cancer; 2021 Jul; 68(7):e29041. PubMed ID: 33851509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of bypassing agents in patients on emicizumab using global hemostasis assays.
    Kizilocak H; Marquez-Casas E; Phei Wee C; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Jan; 27(1):164-172. PubMed ID: 33245833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.
    Ducore J; Lawrence JB; Simpson M; Boggio L; Bellon A; Burggraaf J; Stevens J; Moerland M; Frieling J; Reijers J; Wang M
    Haemophilia; 2017 Nov; 23(6):844-851. PubMed ID: 28984010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real-world evidence.
    Kenet G; Fujii T
    Haemophilia; 2024 Mar; 30(2):267-275. PubMed ID: 38291654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective.
    Miesbach W; Carcao M; Mahlangu J; Dargaud Y; Jimenez-Yuste V; Hermans C
    Haemophilia; 2024 Mar; 30(2):257-266. PubMed ID: 38317441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro.
    Yada K; Fujitate N; Ogiwara K; Soeda T; Kitazawa T; Nogami K
    Thromb Res; 2024 May; 237():37-45. PubMed ID: 38547693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.
    Escobar M; Luck J; Averianov Y; Ducore J; Fernández MFL; Giermasz A; Hart DP; Journeycake J; Kessler C; Leissinger C; Mahlangu J; Martinez LV; Miesbach W; Mitha IH; Quon D; Reding MT; Schved JF; Stasyshyn O; Vilchevska KV; Wang M; Windyga J; Alexander WA; Al-Sabbagh A; Bonzo D; Mitchell IS; Wilkinson TA; Hermans C
    Haemophilia; 2021 Nov; 27(6):911-920. PubMed ID: 34614267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors.
    Pipe SW; Hermans C; Chitlur M; Carcao M; Castaman G; Davis JA; Ducore J; Dunn AL; Escobar M; Journeycake J; Khan O; Mahlangu J; Meeks SL; Mitha IH; Négrier C; Nowak-Göttl U; Recht M; Chrisentery-Singleton T; Stasyshyn O; Vilchevska KV; Martinez LV; Wang M; Windyga J; Young G; Alexander WA; Bonzo D; Macie C; Mitchell IS; Sauty E; Wilkinson TA; Shapiro AD
    Haemophilia; 2022 Jul; 28(4):548-556. PubMed ID: 35475308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A.
    Takeyama M; Nogami K; Matsumoto T; Noguchi-Sasaki M; Kitazawa T; Shima M
    J Thromb Haemost; 2020 Apr; 18(4):825-833. PubMed ID: 31984625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors.
    Furukawa S; Nogami K; Shimonishi N; Nakajima Y; Matsumoto T; Shima M
    Br J Haematol; 2020 Sep; 190(5):727-735. PubMed ID: 32162680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors.
    Pipe SW; Dunn AL; Young G
    Expert Rev Hematol; 2023; 16(10):715-729. PubMed ID: 37602448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.
    Nakajima Y; Tonegawa H; Noguchi-Sasaki M; Nogami K
    Int J Hematol; 2021 Jun; 113(6):789-796. PubMed ID: 33635530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients.
    Tanaka KA; Henderson R; Thangaraju K; Morita Y; Mazzeffi MA; Strauss E; Katneni U; Buehler PW
    Haemophilia; 2022 Jan; 28(1):183-190. PubMed ID: 34735039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma.
    Yada K; Ogiwara K; Shimonishi N; Nakajima Y; Soeda T; Kitazawa T; Nogami K
    Int J Hematol; 2024 Feb; 119(2):109-118. PubMed ID: 38112996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world data.
    Misgav M; Brutman-Barazani T; Budnik I; Avishai E; Schapiro J; Bashari D; Barg AA; Lubetsky A; Livnat T; Kenet G
    Haemophilia; 2021 Mar; 27(2):253-260. PubMed ID: 33595174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
    Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
    Haemophilia; 2019 Sep; 25(5):789-796. PubMed ID: 31373431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-additive effect on thrombin generation when a plasma-derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro.
    Bravo MI; Raventós A; Pérez A; Costa M; Willis T
    J Thromb Haemost; 2020 Aug; 18(8):1934-1939. PubMed ID: 32379931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.